Plasma homovanillic acid and prolactin in huntington's disease

Neurochemical Research

Volumn 34, Issue 5, 2009, Pages 917-922

  Markianos, Manolis ^a   Panas, Marios ^a   Kalfakis, Nikos ^a   Vassilopoulos, Dimitrios ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

Huntington's disease; Plasma homovanillic acid; Prolactin; Severity of illness

Indexed keywords

HOMOVANILLIC ACID; PROLACTIN;

ADULT; AGED; ARTICLE; CLINICAL EVALUATION; CLINICAL FEATURE; CONTROL GROUP; CONTROLLED STUDY; DEMENTIA; DISEASE DURATION; DOPAMINERGIC ACTIVITY; FEMALE; FUNCTIONAL STATUS; HUMAN; HUNTINGTON CHOREA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RATING SCALE; SYMPTOMATOLOGY;

ADULT; AGE OF ONSET; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; DOPAMINE; FEMALE; HALOPERIDOL; HOMOVANILLIC ACID; HUMANS; HUNTINGTON DISEASE; MALE; MIDDLE AGED; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; PROLACTIN; SEVERITY OF ILLNESS INDEX; SEX FACTORS; TRINUCLEOTIDE REPEAT EXPANSION; YOUNG ADULT;

EID: 67349189923     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11064-008-9851-1     Document Type: Article

References (41)

1. Y Luo H Umegaki X Wang 1998 Dopamine induces apoptosis through an oxidation-involved SAPK/JNK activation pathway J Biol Chem 273 3756 3764 10.1074/jbc.273.6.3756 (Pubitemid 28109805)
2. RJ Jakel WE Maragos 2000 Neuronal cell death in Huntington's disease: a potential role for dopamine Trends Neurosci 23 239 245 10.1016/S0166-2236(00) 01568-X (Pubitemid 30331108)
3. A Petersen KE Larsen GG Behr 2001 Expanded CAG repeats in exon 1 of the Huntington's disease gene stimulate dopamine-mediated striatal neuron autophagy and degeneration Hum Mol Genet 10 1243 1254 10.1093/hmg/10.12.1243 (Pubitemid 32600478)
4. JN Joyce N Lexow E Bird 1988 Organization of dopamine D1 and D2 receptors in human striatum: receptor autoradiographic studies in Hubtington's disease and schizophrenia Synapse 2 546 557 10.1002/syn.890020511 (Pubitemid 18241947)
5. J Brandt SE Folstein DF Wong 1990 D2 receptors in Huntington's disease: Positron emission tomography findings and clinical correlates J Neuropsychiatry Clin Neurosci 2 20 27 (Pubitemid 20125840)
6. EK Richfield CF O'Brien T Eskin 1991 Heterogeneous dopamine receptor changes in early and late Huntington's disease Neurosci Lett 132 121 126 10.1016/0304-3940(91)90448-3
7. N Ginovart A Lundin L Farde 1997 PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease Brain 120 503 514 10.1093/brain/120.3.503 (Pubitemid 27153642)
8. TC Andrews RA Weeks N Turjanski 1999 Huntington's disease progression. PET and clinical observations Brain 122 2353 2363 10.1093/brain/122.12.2353
9. JJ Mann M Stanley S Gershon 1980 Mental symptoms in Huntington's disease and a possible primary aminergic neuron lesion Science 210 1369 1371 10.1126/science.6449080 (Pubitemid 11175498)
10. GP Reynolds NJ Garrett 1986 Striatal dopamine and homovanillic acid in Huntington's disease J Neural Transm 65 151 155 10.1007/BF01256491 (Pubitemid 16160395)
11. SJ Kish K Shannak O Hornykiewicz 1987 Elevated serotonin and reduced dopamine in subregionally divided Huntington's disease striatum Ann Neurol 22 386 389 10.1002/ana.410220318 (Pubitemid 17137904)
12. G Curzon J Gumpert D Sharpe 1972 Amine metabolites in the cerebrospinal fluid in Huntington's chorea J Neurol Neurosurg Psychiatry 35 514 519
13. PJ Garcia Ruiz MA Mena V Sanchez Bernardos 1995 Cerebrospinal fluid homovanillic acid is reduced in untreated Huntington's disease Clin Neuropharmacol 18 58 63 10.1097/00002826-199502000-00007
14. R Kurlan D Godblatt R Zaczek 1988 Cerebrospinal fluid homovanillic acid and parkinsonism in Huntington's disease Ann Neurol 24 282 284 10.1002/ana.410240221 (Pubitemid 18206193)
15. IJ Kopin JH White K Bankiewicz 1988 A new approach to biochemical evaluation of brain dopamine metabolism Cell Mol Neurobiol 8 171 179 10.1007/BF00711243 (Pubitemid 18179385)
16. F Amin M Davidson KL Davis 1992 Homovanillic acid measurements in clinical research: A review of methodology Schizophr Bull 18 123 148
17. F Amin M Davidson RS Kahn 1995 Assessment of the central dopaminergic index of plasma HVA in schizophrenia Schizophr Bull 21 53 66
18. GW Lambert G Eisenhofer HS Cox 1991 Direct determination of homovanillic acid release from the human brain, an indicator of central dopaminergic activity Life Sci 49 1061 1072 10.1016/0024-3205(91)90593-Z
19. KL Davis M Davidson RC Mohs 1985 Plasma homovanillic acid concentrations and the severity of schizophrenic illness Science 227 1601 1602 10.1126/science.3975630 (Pubitemid 15119471)
20. D Pickar R Labarka AR Doran 1986 Longitudinal measurements of plasma homovanillic acid levels in schizophrenic patients. Correlations with psychosis and response to neuroleptic treatment Arch Gen Psychiatry 43 669 676 (Pubitemid 16094179)
21. R Davila E Manero M Zumarraga 1988 Plasma homovanillic acid as a predictor of response to neuroleptics Arch Gen Psychiatry 45 564 566 (Pubitemid 18147826)
22. WH Chang TY Chen SK Lin 1990 Plasma catecholamine metabolites in schizophrenics: evidence for two-subtype concept Biol Psychiatry 27 510 518 10.1016/0006-3223(90)90442-5 (Pubitemid 20091994)
23. E Suzuki S Kanba M Nibuya 1994 Longitudinal changes in symptoms and plasma homovanillic acid levels in chronically medicated schizophrenic patients Biol Psychiatry 36 654 661 10.1016/0006-3223(94)91174-6 (Pubitemid 24358512)
24. S Nagaoka N Iwamoto H Arai 1997 First-episode neuroleptic-free schizophrenics: concentrations of monoamines and their metabolites in plasma and their correlations with clinical responses to haloperidol Biol Psychiatry 41 857 864 10.1016/S0006-3223(96)00244-2 (Pubitemid 27158383)
25. JA Posener AF Schatzberg GH Williams 1999 Hypothalamic-pituitary-adrenal axis effects on plasma homovanillic acid in man Biol Psychiatry 45 222 228 10.1016/S0006-3223(97)00550-7 (Pubitemid 29079453)
26. T Sumyyoshi A Roy C-H Kim 2004 Prediction of changes in memory performance by plasma homovanillic acid levels in clozapine-treated patients with schizophrenia Psychopharmacology (Berl) 177 79 83 10.1007/s00213-004-1924-5 (Pubitemid 40109917)
27. AC Solomon JC Stout SA Johnson 2007 Verbal episodic memory declines prior to diagnosis in Huntington's disease Neuropsychologia 45 1767 1776 10.1016/j.neuropsychologia.2006.12.015 (Pubitemid 46386118)
28. RA Sweet BG Pollock BH Mulsant 1997 Associations of plasma homovanillic acid with behavioral symptoms in patients diagnosed with dementia: a preliminary report Biol Psychiatry 42 1016 1023 10.1016/S0006-3223(97)00146-7
29. TJM van der Cammen H Tiemeier MJ Engelhart 2006 Abnormal neurotransmitter metabolite levels in Alzheimer patients with a delirium Int J Geriatr Psychiatry 21 838 845 10.1002/gps.1569 (Pubitemid 44492556)
30. MB Bowers RT Malison JP Seibyl 1998 Plasma homovanillic acid and the dopamine transporter during cocaine withdrawal Biol Psychiatry 43 278 281 10.1016/S0006-3223(97)00293-X (Pubitemid 28085674)
31. I Degrell E Nagy 1990 Correlations between cisternal CSF and plasma concentrations of HVA, MHPG, 5-HIAA, DA, and NA Biol Psychiatry 27 1179 1182 10.1016/0006-3223(90)90055-7
32. Huntington Study Group 1996 Unified Huntington's Disease Rating Scale. Reliability and consistency Mov Disord 11 136 142 10.1002/mds.870110204 (Pubitemid 26082779)
33. I Shoulson S Fahn 1979 Huntington's disease. Clinical care and evaluation Neurology 29 1 3 (Pubitemid 9051179)
34. JP Warner LH Barron DJH Brock 1993 A new polymerase chain reaction (PCR) assay for the trinucleotide repeat that is unstable and expanded on Huntington's disease chromosomes Mol Cell Probes 7 235 239 10.1006/mcpr.1993.1034 (Pubitemid 23232244)
35. M Zumarraga R Davila MA Gonzales-Torres 2007 Inter- and intra-individual variability in the levels of plasma homovanillic acid in schizophrenic patients Prog Neuro-Psychopharm Biol Psychiatry 31 713 719 10.1016/j.pnpbp.2007.01.005 (Pubitemid 46467050)
36. R Labarca H Silva S Jerez 1993 Differential effects of haloperidol on negative symptoms in drug-naïve schizophrenic patients: effects on plasma homovanillic acid Schizophr Res 9 29 34 10.1016/0920-9964(93)90006-5
37. ZJ Zhang M Peet CN Ramchand 2001 Plasma homovanillic acid in untreated schizophrenia-relationship with symptomatology and sex J Psychiatr Res 35 23 28 10.1016/S0022-3956(01)00008-5 (Pubitemid 32233167)
38. DH Hunneman W Jonas M Gabriel 1986 Effect of age on homovanillic and 4-hydroxy-3-methoxymandelic acid levels in plasma Eur J Pediatr 145 555 557 10.1007/BF02429064 (Pubitemid 17041463)
39. M Beuger DP van Kammen ME Kelley 1996 Dopamine turnover in schizophrenia before and after haloperidol withdrawal. CSF, plasma, and urine studies Neuropsychopharmacology 15 75 86 10.1016/0893-133X(95)00158-A (Pubitemid 26233393)
40. A Antonini KL Leenders R Spiegel 1996 Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease Brain 119 2085 2095 10.1093/brain/119.6.2085 (Pubitemid 27032638)
41. T-A Tang X Chen J Liu 2007 Dopaminergic signaling and striatal neurodegeneration in Huntington's disease J Neurosci 27 7899 7910